{"id":782022,"date":"2023-09-06T10:05:13","date_gmt":"2023-09-06T14:05:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/"},"modified":"2023-09-06T10:05:13","modified_gmt":"2023-09-06T14:05:13","slug":"harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/","title":{"rendered":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Sept.  06, 2023  (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed\/refractory multiple myeloma. The presentation will take place at the upcoming 20<sup>th<\/sup> International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece.<\/p>\n<p>Details of the IMS poster presentation are as follows:<\/p>\n<p>\n        <strong>Title: <\/strong>Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac<sup>\u00ae<\/sup>) Targeting B Cell Maturation Antigen (BCMA) for Relapsed\/Refractory Multiple Myeloma (MM)<br \/><strong>Poster Number: <\/strong>P-292 <br \/><strong>Presenter: <\/strong>Sumit Madan, M.D., Banner MD Anderson Cancer Center <br \/><strong>Session\/Location: <\/strong>Poster Session 2, Trianti Hall Level II Foyer <br \/><strong>Date: <\/strong>Thursday, September 28\u00a0\u00a0 <br \/><strong>Time:<\/strong> Viewing \u2013 10:00 to 18:15 EEST \/ 3:00 a.m. to 1:15 p.m. ET, Presentation \u2013 12:30 to 13:30 EEST \/ 5:30 a.m. to 6:30 a.m. ET<\/p>\n<p>The poster will also be available on Harpoon\u2019s website following the presentation.<\/p>\n<p>For more details about the IMS Annual Meeting, please visit: <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PdWRRcZdw3jkWFPOiAthH1xZ632AyKsAgnIPyb4VYT8-QA5ROVcMve67H9uZ33oejlz5F51b3qCIt8afJVrqStJuhO7cLp3k30eFCs8eBw2zRwKRv9V42rB543PJY6p2W-q3M-56LURcVkZKNBudkNEb4lCzo0nrt1-R1ktl3Z8UwhTsPEX9o615IMyqgCs5cvnE0pfN-t9095Cq_4hc0MaXEY4wkJs9HSRBucKbmDFAZ0kVup6d4PuR0riGkDwI\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/events.jspargo.com\/ims23\/Public\/Content.aspx?ID=102336&amp;sortMenu=101000<\/u><\/a><\/p>\n<p>\n        <strong>About Harpoon Therapeutics <\/strong><br \/>\n        <br \/>Harpoon Therapeutics\u00a0is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body\u2019s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient\u2019s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC<sup>\u00ae<\/sup>) platform, Harpoon is developing a pipeline of novel TriTACs\u00a0initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC\u2122\u00a0platform, which applies a prodrug concept to its TriTAC\u00a0platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon\u2019s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MlLjvp_IQpvnsZrGUNgjXZ6C47vTcHaNclstL5R6urL2FQT6u1Rdttsm_q65tzXTMpWotEkCGgzTNwPqQRxqokuFFnKpn7r7Mj2l0FXJd-6ksXO3CFz4T_L6LigwqPDGZlbECVyoRMKhuAXWK_1OHpgW53m0uTuET4sbvCEBbLBPE-1cmGtcMgyIduVNtJ4zz0ccBcZ9EjkUtiZHZ5AU4Z0Ygqewv6fcdKoPeCqzvI8=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.harpoontx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201ccontinue,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to Harpoon\u2019s data presentation plans and other statements that are not historical fact. These forward-looking statements are based on Harpoon Therapeutics\u2019 expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics\u2019 clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. These and other factors that may cause Harpoon Therapeutics\u2019 actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics\u2019 filings with the\u00a0U.S. Securities and Exchange Commission, including under \u201cRisk Factors\u201d in Harpoon Therapeutics\u2019 quarterly report on Form 10-Q for the quarter ended\u00a0June 30, 2023,\u00a0and future filings by\u00a0Harpoon Therapeutics. Except as required by law,\u00a0Harpoon Therapeutics\u00a0assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p>\n        <strong>Contact<\/strong><br \/>\n        <br \/>Investors and Media:<br \/>ICR Westwicke<br \/>Robert H. Uhl<br \/>Managing Director<br \/>858-356-5932 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Yw3WF7Ss_niMEV0UQkHTQPQmE3sWHf40CqeIYPqy9XGFpSfK22SfVM9rYGmDXBWSGQt-ZO9SRKbSAxzpxPEJouLVMvYCwA5b3C_V0UiVJw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>robert.uhl@westwicke.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzA4OTcwYjMtMTJjMC00Y2U4LWI3NzMtMmM1NDg1Y2IyOTgwLTExMzczODM=\/tiny\/Harpoon-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed\/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece. Details of the IMS poster presentation are as follows: Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac\u00ae) Targeting B Cell Maturation Antigen (BCMA) for Relapsed\/Refractory Multiple Myeloma (MM)Poster Number: P-292 Presenter: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-782022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed\/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece. Details of the IMS poster presentation are as follows: Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac\u00ae) Targeting B Cell Maturation Antigen (BCMA) for Relapsed\/Refractory Multiple Myeloma (MM)Poster Number: P-292 Presenter: &hellip; Continue reading &quot;Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-06T14:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting\",\"datePublished\":\"2023-09-06T14:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/\"},\"wordCount\":603,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/\",\"name\":\"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\",\"datePublished\":\"2023-09-06T14:05:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) &#8212; Harpoon Therapeutics, Inc.\u00a0(Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced abstract acceptance and a poster presentation of preliminary data (up to and including 12mg cohorts) from the dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed\/refractory multiple myeloma. The presentation will take place at the upcoming 20th International Myeloma Society (IMS) Annual Meeting being held September 27-30, 2023 in Athens, Greece. Details of the IMS poster presentation are as follows: Title: Ongoing Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTac\u00ae) Targeting B Cell Maturation Antigen (BCMA) for Relapsed\/Refractory Multiple Myeloma (MM)Poster Number: P-292 Presenter: &hellip; Continue reading \"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-06T14:05:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting","datePublished":"2023-09-06T14:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/"},"wordCount":603,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/","name":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=","datePublished":"2023-09-06T14:05:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNzE5NCM1ODAwMTE0IzIxMjU4MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/harpoon-therapeutics-abstract-for-hpn217-accepted-for-poster-presentation-at-the-20th-international-myeloma-society-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=782022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/782022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=782022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=782022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=782022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}